Farnesyl transferase inhibitors: the successes and surprises of a new class of potential cancer chemotherapeutics

Chemistry and Biology

Volumn 2, Issue 12, 1995, Pages 787-791

  Buss, Janice E ^a   Marsters Jr , James C ^b  

^a IOWA STATE UNIVERSITY   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; P21(RAS) FARNESYL PROTEIN TRANSFERASE; P21(RAS) FARNESYL-PROTEIN TRANSFERASE; TRANSFERASE;

ANIMAL; DRUG ANTAGONISM; EXPERIMENTAL NEOPLASM; GENETICS; ONCOGENE RAS; RAT; REVIEW;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; GENES, RAS; NEOPLASMS, EXPERIMENTAL; RATS;

ANIMALIA;

EID: 0029613291     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/1074-5521(95)90083-7     Document Type: Short Survey

References (26)

1. ras genes
2. Protein prenylation molecular mechanisms and functional consequences
3. Ras C-terminal processing enzymes - new drug targets?
4. Selective inhibition of farnesyl-protein transferase blocks Ras processing in vivo
5. Ras farnesylation as a target for novel antitumor agents: potent and selective farnesyl diphosphate analog inhibitors of farnesyltransferase
6. Peptidomimetic inhibitors of Ras farnesylation and function in whole cells
7. Selective inhibition of ras dependent transformation by a farnesyltransferase inhibitor
8. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton
9. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice
10. A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing
11. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells
12. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion
13. NMR studies of novel inhibitors bound to farnesyl-protein transferase
14. Novel tricyclic inhibitors of farnesyl protein transferase
15. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells
16. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
17. Mutant ras oncogenes upregulate VEGFNPF expression: implications for induction and inhibition of tumor angiogenesis
18. Dominant inhibitory Ras mutants selectively inhibit the activity of either cellular or oncogenic Ras
19. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes
20. Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-Ras-transformed Rat-1 cells, but not in untransformed cells
21. The farnesyl protein transferase inhibitor BZA-5B blocks farnesylation of nuclear lamins and p21 ras but does not affect their function or localization
22. CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB
23. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro
24. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyl-transferase I inhibitor
25. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras/TC21 transformation
26. Farnesol is utilized for protein isoprenylation and the biosynthesis of cholesterol in mammalian cells